Islam Y Elgendy is an expert in Cardiology at University of Kentucky (United States). As of October 2026, ScienceLeadR ranks Islam Y Elgendy in the top 1% of experts worldwide for Myocardial Ischemia, and in the top 1% of experts in the United States for Embolism and Thrombosis. Islam Y Elgendy has authored 614 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 2,182 (community average: 125). How the SLR is computed.

LeadR Profile

Islam Y Elgendy University of Kentucky United States
2 182 ScienceLeadR Reputation 2182
Network Map

Cardiology

Subspecialties: Public Health - Internal Medicine - Biostatistics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2026

Source: PubMed

Harvard University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 614

Citations

Citations: 58 544 1st author: 91 Last author: 156 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Trends in mortality involving atrial fibrillation/flutter and renal failure in the United States, 1999-2023: A nationwide multiple-cause-of-death analysis.
PMID 42937783 — mortality, atrial flutter, cause of death, atrial fibrillation, aged, centers for disease control and prevention, u.s., diagnosis, records, death certificates
Medicine (Baltimore)20260
Cardiovascular outcomes of SGLT2 inhibitors across the spectrum of myocardial infarction: A systematic review and meta-analysis.
PMID 42928993 — diabetes mellitus, sodium-glucose transporter 2 inhibitors, mortality, hospitalization, stroke, myocardial infarction, heart failure, pharmaceutical preparations, heart, pharmacology
Br J Clin Pharmacol20260
Comparative Outcomes of Self-Expanding Versus Balloon-Expandable Valves in Severe Aortic Stenosis: A Systematic Review and Meta-Analysis.
PMID 42928070 — constriction, pathologic, mortality, aortic valve stenosis, hospitalization, stroke, heart failure, heart, cardiovascular diseases, transcatheter aortic valve replacement
Cardiol Rev20260
Timing of Nonculprit PCI for STEMI and Multivessel Disease.
PMID 42863872 — st elevation myocardial infarction
JACC Cardiovasc Interv20260
High-Potency P2Y12 Inhibitors Among Patients With Chronic Coronary Syndrome Undergoing PCI: An Analysis From the NCDR CathPCI Registry.
PMID 42861503 — registries, myocardial infarction, ticagrelor, percutaneous coronary intervention, clopidogrel, prescriptions, arteries, odds ratio, coronary artery bypass
Circ Cardiovasc Interv20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 2 1
Phase 4 1

By status:

Completed 3

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map